Trends in New Use of Disease‐Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022
Authors' conclusion
Among commercially insured children with JIA in the United States, new b/tsDMARD use is rising and new csDMARD use is declining.
Study context
- Population
- Commercially insured children aged 1 to 18 diagnosed with juvenile idiopathic arthritis (JIA), United States
- Participants
- 13,696 participants20,258 new disease-modifying antirheumatic drug (DMARD) use episodes
- Outcome
- New DMARD initiations (csDMARD, bDMARD, tsDMARD) as a percentage of all new DMARD initiations per year, by category, class and agent
- Follow-up
- 2001-2022
Methodological detailscommercial claims data (2000-2022), ≥12-month baseline, linear regression for trends
- Commercial claims data (2000-2022)
- ≥12-month baseline
- Linear regression for trends
Main finding
As reported in the abstract
Share of new DMARD use episodes, 2001-2022
bDMARD use increased; P < 0.001
10.5-50.0%
Etanercept peaked at 28.3% in 2006 and declined to 4.2% in 2022; P = 0.002
28.3% to 4.2%
Adalimumab use doubled after JIA approval (2007-2008), increasing further after less painful formulation release; 20.5% in 2022, P < 0.001
7.0-14.0%
Observational data: associations, not effects.
Further findings
First b/tsDMARD initiated after csDMARDs · 2022
- Adalimumab most common
- 77.8%
Original publication
Trends in New Use of Disease‐Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022. Arthritis Rheumatol. Published 10 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →